IMUGENE CHART. TA only, page-18418

Well said. Balance sheet management is exec bread and butter.

Who wants their execs to turn down $80m cash plus a commitment for more $$ to come in time.

It's a no brainer.

Plus at the way the cash rate is going, there's money to be made in short term money markets for companies with $175m cash and counting... not too mention biotech is inflation agnostic (unless lab costs increase, which is possible). However, this is softened by interest made on $175m plus ongoing R&D government subsidies.

Inflation is not going to hurt the IP but the conpany's ability to garner capital investment in the future might if financiers get spooked by macros

Win win win